Artificial Intelligence Model for Growth Prediction of Ovarian Cancer Organoids
Development and Validation of Growth Prediction Model for Ovarian Cancer Organoids Based on Bright Field Image and Deep Learning
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Dongling Zou, MD
- Phone Number: 13657690699
- Email: cqzl_zdl@163.com
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 400030
- Recruiting
- Chongqing Cancer Hospital
-
Principal Investigator:
- Dongling Zou, M.D.
-
Contact:
- Dongling Zou, M.D.
- Phone Number: 13657690699
- Email: cqzl_zdl@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients must have histologically confirmed diagnosis of epithelial ovarian cancer
- Patients received biopsy or puncture to obtain tumor tissues or malignant effusion
- Patients voluntarily participated in the study and signed informed consent.
Exclusion Criteria:
- Non-epithelial ovarian cancer
- No sufficient amount of tumor tissues or malignant effusion for organoids establishment.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AUC of growth prediction performance using deep learning model
Time Frame: up to 3 years
|
AUC =Area under receiver operating characteristic curve
|
up to 3 years
|
|
Accuracy of growth prediction using deep learning model
Time Frame: up to 3 years
|
Accuracy=( the number of correctly classified samples)/( the number of total samples)
|
up to 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Dongling Zou, M.D., Chongqing University Cancer Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
Other Study ID Numbers
- CQGOG0206
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.